We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 5989G
Silence Therapeutics PLC
05 March 2018
Silence Therapeutics to Present at the Cowen 38th Annual Health Care Conference
London, 5(th) March 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that Ali Mortazavi, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston, MA.
The presentation will be webcast live and may be accessed by visiting Silence's website at http://www.silence-therapeutics.com/investors/. A replay of the webcast will be available for 14 business days.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457 Ali Mortazavi, Chief Executive 6900 Officer David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Tel: +44 (0)20 7418 Adviser and Broker) 8900 James Steel/Oliver Jackson Media Enquiries: Optimum Strategic Communications Tel: +44 (0) 20 3714 Mary Clark/ Eva Haas/Hollie 1788 Vile silence@optimumcomms.com IR Enquires - US Tel: +1 (212) 213 Burns McClellan 0006 John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJTMFTMBIMBIP
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions